We examined the expression of the four predominant cell cycle cyclins and CDKs to establish if inhibition of CDK4/6 by palbociclib was associated with alteration of CDKs or cyclins that have been implicated in acquisition of resistance to palbociclib in luminal breast cancer [31]. This evidence concerns the gene CDK4 and breast cancer.